Skip to content

Search

Home participation resource for children with disability and complex needs

For families with a child with disability, this involves many extra care duties especially if their child has high and complex needs.

Tips for discussing coronavirus with your kids

The rapidly developing coronavirus crisis is affecting our daily lives in unprecedented ways and brings with it uncertainty and fear.

COVID-19 information

The situation with COVID-19 is constantly evolving, and there is an extraordinary amount of information circulating which can be both overwhelming and difficult to navigate.

What parents should know about coronavirus

Schools are issuing restrictions around attendance after travel overseas due to coronavirus. Here's how to prepare your kids against the spread of infectious disease on their return to school.

Perth researchers lead world-first clinical trial in Chile to stop COVID-19 outbreaks

Perth researchers are leading an international clinical trial focused on preventing the spread of COVID-19 by testing the effectiveness of the drug interferon in reducing the infectiousness of people who contract the virus.

Community immunity: Developing a sensitive and specific SARS-CoV-2 antibody test

Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group

ORIGINS community wellbeing during the COVID-19 pandemic

Desiree Dr Jackie Lisa Susan Silva Davis Gibson Prescott MBBS, FRACP, MPH, PhD BSc (Hons), PGradDipHlthProm, PhD BA (Hons), MPsych, PhD MBBS BMedSci

UV light and COVID-19

Investigator: Nisali Gamage Project description We critically review new studies which are emerging that report findings related to the effects of UV

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference

Vaccination has been a cornerstone of public health, substantially reducing the global burden of infectious diseases, notably evident during the COVID-19 pandemic caused by SARS-CoV-2.